In preclinical studies, the blockade of CTLA-4 led to a 1.5–2-fold increase in T-cell proliferation, enhanced IL-2 production [127], and depleted Treg in the tumor microenvironment [128]. This evidence concerns the gene CTLA4 and neoplasm.